Talk:Intarcia Therapeutics

Page contents not supported in other languages.
From Wikipedia, the free encyclopedia

Intarcia - edits[edit]

Hello,

I am an employee of Intarcia and would like to help update the Wikipedia entry for the company. There are a few inaccuracies and additions that are needed and I would like to work with you on to ensure I am updating them properly and according to Wikipedia guidelines.

I look forward to working with you. Thanks IntarciaEd (talk) 19:33, 28 September 2016 (UTC)[reply]

Some proposed changes[edit]

Hello,
I’ve detailed out below some edits that I would like to implement on this page.

In the infobox under ‘key people,’ remove the ‘/’ symbols for Kurt C. Graves’ title. This should read Kurt C. Graves (Chairman, President and CEO). Also remove James M. Ahlers and Michelle A. Baron from the ‘key people’ section.

For the products section of the infobox, remove text that says ‘(none as of 2012)’ and replace with ‘Medici Drug Delivery System™.’ Here’s the source: http://www.medgadget.com/2016/06/intarcia-medici-tiny-implantable-pump-drug-delivery.html

In paragraph one, sentence one, please replace ‘pharmaceutical company’ with ‘biopharmaceutical company’ and replace ‘Hayward, California’ with ‘Boston, MA.’ The same sources on the sentence are still relevant. Therefore, the first sentence should read: Intarcia Therapeutics is an American biopharmaceutical company based in Boston, MA and incorporated under the laws of Delaware.

Delete sentence three of paragraph one that begins “In April 2012, the company announced…” This information is no longer current. Instead, please add in the following sentences in its place: In Fall 2013, Intarcia relocated its headquarters to Boston, keeping its manufacturing facility in Hayward, CA. In addition to Boston and Hayward, Intarcia also has a location in Research Triangle Park, North Carolina, where it discovers and develops peptides for its drug delivery system.
The source for the sentence beginning “In Fall 2013…” is http://www.fiercebiotech.com/r-d/investors-pump-200m-into-intarcia-s-phiii-for-once-yearly-diabetes-therapy. The source for the sentence beginning “In addition to Boston…” is http://directory.ncbiotech.org/content/intarcia-therapeutics-inc.

Please add an additional sentence to the end of paragraph two after the sentence beginning, “By 2012, Kurt Graves…” Add: Kurt Graves has been with Intarcia since August 2010, first serving as Executive Chairman before becoming President and CEO in April 2012.
The source for this new sentence is: http://www.bloomberg.com/research/stocks/people/person.asp?personId=23871652&privcapId=36235.

For paragraph three:

  • “As of 2012…” please change ‘2012’ to ‘2016.’
  • Sentence two, please remove the hyphen in ‘ITCA-650,’ this should read ‘ITCA 650.’
  • Sentence two, replace ‘DUROS system’ with ‘Medici Drug Delivery System™.’ The DUROS system name is no longer accurate. The source for the new ‘Medici Drug Delivery System’ name is http://www.medgadget.com/2016/06/intarcia-medici-tiny-implantable-pump-drug-delivery.html.
  • Please add a new sentence after the sentence that reads “Referred to as…” The additional sentence should read: The Medici Drug Delivery System™ is comprised of three unique technologies: 1) an osmotic mini-pump that is placed just beneath the skin to deliver a continuous and consistent flow of medication; 2) mini-pump placement technology; and 3) high temperature therapeutic stabilization technology.

The source for this new sentence is http://www.diabetesincontrol.com/freedom-2-trial-results-for-itca-650/.

Under the ‘Investors’ section, please add the following new paragraphs under the existing copy within this section:
In April 2014, Intarcia secured an additional $200M in financing. RA Capital led the round and was joined by new and existing investors.

In April 2015, the company raised $225M in exchange for 1.5% of future global net sales of ITCA 650.

In May 2016, Intarcia secured an additional $75M in financing to scale-up manufacturing and inventory in anticipation of ITCA 650’s global launch.

In September 2016, Intarcia raised an additional $215M in equity financing to prepare for the commercial launch of ITCA 650 in late 2017 and additional pipeline programs.
The sources for the above paragraphs are as follows:


Once these changes have been made, please remove the stub status from the page.

Thanks for your help IntarciaEd (talk) 23:25, 7 October 2016 (UTC)[reply]

Done, looks ok to me Aloneinthewild (talk) 20:58, 23 May 2017 (UTC)[reply]

Some proposed changes[edit]

Hello,
I’ve detailed out below some edits that I would like to implement on this page.

After the intro section and before the Investors section, please create a new section titled:

History[edit]


In this section, please add the following new paragraphs:
In December 2011, Intarcia brought on Quintiles to become a financial and strategic partner for the global clinical development of ITCA 650.

In November 2014, Intarcia entered into a licensing deal with French drug firm Servier, granting them exclusive rights to ITCA 650 outside of the United States and Japan.

In March 2015, Intarcia announced a strategic collaboration with Numab AG to develop once or twice yearly antibodies to address diabetes, obesity and autoimmune diseases.

In September 2015, Intarcia acquired Phoundry Pharmaceuticals, formerly part of the Enteroendocrine Discovery Performance Unit of GlaxoSmithKline. Phoundry brings a portfolio of optimized peptides in various therapeutic categories, including diabetes and obesity.

The sources for the above paragraphs are as follows:


After the newly added History section, please add another new section titled:

Pipeline[edit]


In this section, please add the following text:
Paragraph one should read: Intarcia has completed its FREEDOM Phase 3 clinical trial program for ITCA 650, comprised of four Phase 3 studies:
The source for this sentence is: http://www.ajmc.com/newsroom/intarcia-announces-cv-results-needed-for-fda-approval-of-diabetes-therapy-delivery.

Beneath the sentence beginning “Intarcia has completed its FREEDOM…”, please add the following bullets:
Bullet #1 should read: *FREEDOM-1: double-blind study against a placebo in type 2 diabetes patients with an HbA1c between 7.5% to 10%.
Bullet #2 should read: *FREEDOM-1 HBL: open label study in type 2 diabetes patients with an HbA1c between 10% to 12%.
The source for both bullets 1 and 2 is: http://www.diabetesincontrol.com/two-positive-phase-3-trials-for-itca-650-a-glp-1-agonist-in-type-2-diabetes/.

Bullet #3 should read: *FREEDOM-2: randomized controlled study in type 2 diabetes patients taking metformin, comparing ITCA 650 to sitagliptin.
The source for bullet 3 is: http://www.ajmc.com/conferences/ada2016/after-a-year-itca-650-produces-lower-a1c-more-weight-loss-than-sitagliptin.

Bullet #4 should read: *FREEDOM-CVO: cardiovascular safety study against a placebo in 4,000 type 2 diabetes patients.
The source for bullet 4 is: http://www.ajmc.com/conferences/ada2016/after-a-year-itca-650-produces-lower-a1c-more-weight-loss-than-sitagliptin.

Beneath these bullets, please add a new paragraph of text that reads: In addition to its FREEDOM clinical trial program, Intarcia is working to advance its product pipeline, aiming to develop new once or twice-yearly antibody-based therapies and combinations for diabetes, obesity and autoimmune diseases.
The source for this sentence is: http://www.massdevice.com/intarcia-adds-225m-type-ii-diabetes-trial/.

Following the existing Notes section, please create a new section titled:

External links[edit]


Within this new External links section, please add the following bullets:


Thanks for your help IntarciaEd (talk) 15:05, 31 October 2016 (UTC)[reply]

Retrieved from "https://en.wikipedia.org/w/index.php?title=Talk:Intarcia_Therapeutics&oldid=1202588383"